Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 29 Aug 2025
All cells naturally produce formaldehyde as a byproduct of metabolism. To survive this toxic stress, both healthy and cancerous blood-forming cells rely on a built-in defense system. Now, scientists at the Lewis Katz School ...
Read Full NewsA trial evaluates whether very early FDG PET-guided treatment adaptation after one cycle of brentuximab vedotin-based chemotherapy improves outcomes in Hodgkin lymphoma.
Researchers report that digital monitoring tools may improve symptom tracking, but nurses face added demands linked to alert verification and patient support.
Triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy do not gain a survival benefit from adding atezolizumab to adjuvant capecitabine, shows trial.
Patients treated with datopotamab deruxtecan reported longer preservation of quality of life and physical functioning vs chemotherapy in metastatic TNBC.
The Oncologic Drugs Advisory Committee backed the prostate cancer drug but rejected a novel approach for breast cancer, highlighting challenges in defining clinical meaningfulness.
A phase 3 trial evaluates the efficacy and safety of nilotinib with pegylated interferon alfa-2a in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Amid a de-escalation trend in breast cancer treatment, less than one third of patients with inflammatory breast cancer receive guideline-endorsed trimodal therapy, despite survival benefits.
1.
A Texas study found that the majority of pancreatic cancer patients do not receive life-saving surgery.
2.
Common intracellular toxin could help fight leukemia
3.
Early breast cancer detection may be possible with a wearable ultrasound scanner.
4.
Adjuvant therapy for hepatocellular carcinoma after curative treatment: Several unanswered questions
5.
Males with early-onset colorectal cancer are at risk, according to a study.
1.
Unveiling Tumor Immunity: Pan-Cancer Proteogenomics Characterization
2.
The Role of the Oncology Pharmacist: From Treatment to Trials and Beyond
3.
Oncology Partnerships: Driving Innovation Through Strategic Collaborations and Pharma Engagement USA
4.
Exploring the Use of Bevacizumab in Treating Different Types of Cancers
5.
Pharmacological Frontier of Precision Oncology, Immunotherapies, and the Evolving Art of Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
2.
Current Scenario of Blood Cancer- Genomic Testing & Advancement in Diagnosis and Treatment
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
5.
From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge